Go on a family-friendly outing this week at Zoo Lights, or skate around the Sculpture Garden ... Canadian composer and musician Caribou performs live at the Anthem (Tues, $35+, Wharf).

Caribou Biosciences is winnowing down for the second time in the last year, dropping a leukemia CAR-T asset and laying off 32% of staff to home in on two lead allogeneic cell therapy candidates.

BERKELEY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced a strategic ...

Shares of Caribou Biosciences (NASDAQ:CRBU) will be in focus on Friday after the gene-editing biotech announced plans to prioritize its lead oncology clinical programs, CB-010 and CB-011 ...

Caribou Biosciences is narrowing its pipeline and reducing its workforce by approximately 32% amid continued challenges in the cell and gene therapy sector. The company announced on 24 April it is ...

At the risk of stealing my Indiecast co-host’s bit, the question isn’t whether Caribou has passed the Five Albums Test. If it’s just a matter of making five great albums in a row ...

Caribou Biosciences’ 2025 outlook aimed for key trial readouts for two cancer cell therapies in the first half of the year and the start of clinical testing in an autoimmune disease. The CRISPR ...

April 24, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced a strategic pipeline ...

Caribou Biosciences, Inc. (NASDAQ:CRBU – Get Free Report) has been assigned a consensus recommendation of “Buy” from the five analysts that are covering the firm, MarketBeat reports.

You can reach Adam on Signal at stataf.54. Caribou Biosciences is delaying the readout of clinical trials involving its CRISPR T-cell therapies for blood cancer — hoping that longer follow-up ...